bbo-10203
Generic: RAS/PI3K-alpha Interaction Inhibitor BBO-10203·Code: BBO-10203
bbo-10203: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Phase 1 |
Clinical Trials (1)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)
Frequently asked questions
Who is developing bbo-10203?
bbo-10203 is being developed by BridgeBio Oncology Therapeutics, Inc..
How many clinical trials involve bbo-10203?
BioSniper tracks 1 clinical trial involving bbo-10203.
Get deeper analysis on bbo-10203
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis